StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Regenxbio's EV/EBITDA was 3.2× on Jan 31, 2023, against 14.7× a year earlier. Over the last 2 years it ranged from 1.0× to 39.5×, with a median of 14.1×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 20233.2×+0.2
2022Dec 30, 20223.0×−11.6
2019Apr 30, 201914.7×+0.5
2018Dec 31, 201814.1×–

More Regenxbio figures

See a number that looks wrong?